Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease

Movement Disorders

Volumn 25, Issue 11, 2010, Pages 1723-1732

  Marti, Matteo ^a   Sarubbo, Silvio ^b   Latini, Francesco ^b   Cavallo, Michele ^b   Eleopra, Roberto ^c   Biguzzi, Sara ^c   Lettieri, Christian ^c   Conti, Carlo ^c   Simonato, Michele ^a   Zucchini, Silvia ^a   Quatrale, Rocco ^b   Sensi, Mariachiara ^b   Candeletti, Sanzio ^d   Romualdi, Patrizia ^d   Morari, Michele ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c Angel's Hospital of Mestre   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

6 OHDA; Cerebrospinal fluid; Haloperidol; Human; Nociceptin orphanin FQ; Parkinson's disease

Indexed keywords

HALOPERIDOL; NOCICEPTIN;

AKINESIA; ANIMAL EXPERIMENT; ARTICLE; BRAIN DEPTH STIMULATION; CAUDATE NUCLEUS; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; GLOBUS PALLIDUS; HUMAN; MALE; MICRODIALYSIS; MOTOR CORTEX; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; THALAMUS;

ADRENERGIC AGENTS; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HALOPERIDOL; HUMANS; MALE; MICRODIALYSIS; MIDDLE AGED; OPIOID PEPTIDES; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; YOUNG ADULT;

EID: 77955815288     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23271     Document Type: Article

References (48)

1. Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/Nociceptin peptide and receptor family. Pharmacol Rev 2001;53:381-415.
2. Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 2008;7:694-710.
3. Marti M, Mela F, Guerrini R, Calò G, Bianchi C, Morari M. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem 2004;91:1501-1504. (Pubitemid 39658576)
4. Marti M, Mela F, Fantin M, et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 2005;95:9591-9601.
5. Mabrouk OS, Marti M, Morari M. Endogenous nociceptin/ orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/ orphanin FQ receptor knockout mice. Neuroscience 2010;166: 40-48.
6. Marti M, Trapella C, Viaro R, Morari M. The Nociceptin/Orphanin FQ Receptor antagonist J-113397 and L-Dopa additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 2007;27:1297-1307. (Pubitemid 46255443)
7. Marti M, Trapella C, Morari M. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through overinhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. J Neurochem 2008;107:1683-1696.
8. Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis 2008;30:430-438.
9. Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2008;23:1922-1925.
10. Di Benedetto M, Cavina C, D'Addario C, et al. Alterations of N/ OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP1 and 6-OHDA lesioned rats. Neuropharmacology 2009;56:761-767.
11. Brown JM, Gouty S, Iyer V, Rosenberger J, Cox BM. Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression. J Neurochem 2006;98:495-505. (Pubitemid 44133153)
12. Marti M, Mela F, Veronesi C, et al. Blockade of nociceptin/ orphanin FQ receptor signalling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behaviour. J Neurosci 2004;24:6659-6666. (Pubitemid 38993885)
13. Kuzmin A, Bazov I, Sheedy D, Garrick T, Harper C, Bakalkin G. Expression of pronociceptin and its receptor is downregulated in the brain of human alcoholics. Brain Res 2009;11:1305(suppl): S80-S85.
14. Rocha L, Orozco-Suarez S, Alonso-Vanegas M, et al. Temporal lobe epilepsy causes selective changes in mu opioid and nociceptin receptor binding and functional coupling to G-proteins in human temporal neocortex. Neurobiol Dis 2009;35:466-473.
15. Hantos MB, Szalay F, Lakatos PL, et al. Elevated plasma nociceptin level in patients with Wilson disease. Brain Res Bull 2002;58:311-313. (Pubitemid 34786464)
16. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 2007;30:317-337.
17. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Sydney: Academic Press, 1982.
18. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970;24:485-493.
19. Marti M, Mela F, Bianchi C, Beani L, Morari M. Striatal dopamine- NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J Neurochem 2002;83:635-644. (Pubitemid 35231817)
20. Bregola G, Zucchini S, Rodi D, et al. Involvement of the neuro-peptide nociceptin/orphanin FQ in kainate seizures. J Neurosi 2002;22:10030-10038. (Pubitemid 35332888)
21. Simonato M, Bregola G, Donatini A, et al. Kindled seizure-induced c-fos and prodynorphin mRNA expressions are unrelated in the rat brain. Eur J Neurosi 1996;8:2064-2067. (Pubitemid 26345778)
22. Aparicio LC, Candeletti S, Binaschi A, et al. Kainate seizures increase nociceptin/orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study. J Neurochem 2004;91:30-37. (Pubitemid 39314934)
23. Ploj K, Roman E, Gustavsson L, Nylander I. Basal levels and alcohol-induced changes in nociceptin/orphanin FQ, dynorphin, and enkephalin levels in C57BL/6J mice. Brain Res Bull 2000;53:219-226.
24. Sanberg PR, Bunsey MD, Giordano M, Norman AB. The catalepsy test: its ups and downs. Behav Neurosci 1988;102:748-759.
25. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria For Parkinson Disease. Arch Neurol 1999;56:33-39.
26. Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Watson SJ Jr. Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol 1999;406:503-547. (Pubitemid 29144937)
27. Norton CS, Neal CR, Kumar S, Akil H, Watson SJ. Nociceptin/ orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems. J Comp Neurol 2002;444:358-368. (Pubitemid 34194922)
28. Lacey MG, Mercuri NB, North RA. Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids. J Neurosci 1989;9:1233-1241.
29. Yung WH, Häusser MA, Jack JJ. Electrophysiology of dopaminergic and non-dopaminergic neurones of the guinea-pig substantia nigra pars compacta in vitro. J Physiol 1991;436:643-667.
30. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosi 1989;12:366-375.
31. Hassani OK, Mouroux M, Féger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996;72:105-115.
32. Conner-Kerr TA, Simmons DR, Peterson GM, Terrian DM. Evidence for the corelease of dynorphin and glutamate from rat hippocampal mossy fiber terminals. J Neurochem 1993;61:627-636.
33. Cobb WS, Abercrombie ED. Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatoden-dritic dopamine release in substantia nigra is dopamine-dependent. Neuroscience 2003;119:777-786.
34. Buzas B, Symes AJ, Cox BM. Regulation of nociceptin/orphanin FQ gene expression by neuropoietic cytokines and neurotrophic factors in neurons and astrocytes. J Neurochem 1999;72:1882-1889.
35. Strömberg I, Björklund H, Dahl D, Jonsson G, Sundström E, Olson L. Astrocyte responses to dopaminergic denervations by 6- hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohisto-chemistry. Brain Res Bull 1986;17:225-236.
36. Raffaeli W, Samolsky DBG, Landuzzi D, et al. Nociceptin levels in the cerebrospinal fluid of chronic pain patients with or without intrathecal administration of morphine. J Pain Symptom Manage 2006;32:372-377.
37. Almay BG, Häggendal J, von Knorring L, Oreland L. 5-HIAA and HVA in CSF in patients with idiopathic pain disorders. Biol Psychiatry 1987;22:403-412.
38. Eklundh T, Eriksson M, Sjöberg S, Nordin C. Monoamine precursors, transmitters and metabolites in cerebrospinal fluid: a prospective study in healthy male subjects. J Psychiatr Res 1996; 30:201-208.
39. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, Oakes D. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group Neurology 1992;42:2111-2117.
40. Facchinetti F, Petraglia F, Cicero S, Nappi G, Valentini M, Genazzani AR. No gradient exists between lumbar and ventricular cerebrospinal fluid beta-endorphin. Neurosci Lett 1987;77:349-352.
41. Berrettini WH, Nurnberger JI Jr, Di Maggio DA. Neuropeptide Y immunoreactivity in human cerebrospinal fluid Peptides. 1986; 7:455-458.
42. Nutt JG, Mrox EA, Leeman SE, Williams AC, Engel WK, Chase TN. Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction. Neurology 1980; 30:1280-1285.
43. Abbott NJ. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 2004; 45:545-552.
44. Nothacker HP, Reinscheid RK, Mansour A, et al. Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci U S A 1996;93:8677-8682.
45. Witta J, Palkovits M, Rosenberger J, Cox BM. Distribution of nociceptin/orphanin FQ in adult human brain. Brain Res 2004; 997:24-29.
46. Johanson CE, Duncan JA III, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res 2008;14:5-10.
47. Candeletti S, Ferri S. Effects of an antisense oligonucleotide to pronociceptin and long-term prevention of morphine actions by nociceptin. Peptides 2000;21:1119-1124.
48. Marti M, Viaro R, Guerrini R, Franchi G, Morari M. Nociceptin/ orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata. Neuropsychopharmacology 2009;34: 341-355